ViroPharma's Buccolam® (Midazolam, Oromucosal Solution) Licensed in Ireland for Emergency Treatment of Seizures in Children and Adolescents

ViroPharma's Buccolam® (Midazolam, Oromucosal Solution) Licensed in Ireland for Emergency Treatment of Seizures in Children and Adolescents PR Newswire EXTON, Pennsylvania, June 27, 2012 EXTON, Pennsylvania, June 27, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) has announced today that ®Buccolam (midazolam, oromucosal solution) is approved for reimbursement by the Health Services Executive (HSE) in Ireland and is available through the national health system for children and adolescents, from three months to less [1]than 18 years of age, who suffer from prolonged, acute, convulsive seizures. In Ireland, there are up to 42,000 patients with epilepsy and it is estimated that [2,3]one in every 200 children has the condition. For children aged between five and 18 years old, the national prevalence is between three and five people in [2]every 1,000, or up to 5,000 in total. For infants between three to six months of age, treatment with Buccolam must be administered in a hospital setting where monitoring is possible and [1]resuscitation equipment is available. Buccolam must only be used by parents [1]or carers where the patient has been diagnosed to have epilepsy. "Buccolam, as a licensed preparation of buccal midazolam for emergency treatment of prolonged seizures, is a welcome additional option for care of children with epilepsy," commented Dr Bryan Lynch, Consultant Paediatric Neurologist at the Children's University Hospital in Dublin.